RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rigel Pharmaceuticals Inc (RIGL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive growth trends, and neutral trading sentiment make it a suitable choice for long-term holding.
The MACD is positive at 0.784, indicating bullish momentum, though it is contracting. RSI at 74.593 is neutral, showing no overbought or oversold conditions. Moving averages are converging, suggesting consolidation. The pre-market price of $31.77 is near the R1 resistance level of $31.731, indicating potential for a breakout.
The company's financials for Q4 2025 showed significant growth: Revenue increased by 21.19% YoY, Net Income surged by 1769.22% YoY, and EPS rose by 1557.50% YoY. Gross Margin also improved to 91.47%.
No significant news or events in the past week. Stock trend analysis indicates a 70% chance of minor price changes (-0.27% next day, 0.29% next week, -0.81% next month), suggesting limited short-term upside.
In Q4 2025, Rigel Pharmaceuticals reported robust financial growth with Revenue at $69.8M (up 21.19% YoY), Net Income at $268.07M (up 1769.22% YoY), EPS at 13.26 (up 1557.50% YoY), and Gross Margin at 91.47% (up 1.69% YoY).
No recent updates on analyst ratings or price target changes. Hedge funds and insiders are neutral, indicating no strong sentiment from institutional or insider activity.
